Journal of Research and Practice on the Musculoskeletal System
JRPMS

Review Article

Anti-Sclerostin Antibodies in the Treatment of Metabolic Bone Diseases

Ourania Trantafili[1], George I. Lambrou[1,2,3,4]

[1]*Postgraduate Program "Metabolic Bones Diseases", National and Kapodistrian University of Athens, Medical School, Goudi, Athens, Greece;*
[2]*Laboratory for the Research of the Musculoskeletal System "Th. Garofalidis", National and Kapodistrian University of Athens, Medical School, Kifissia, Athens, Greece;*
[3]*Choremeio Research Laboratory, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Goudi, Athens, Greece;*
[4]*University Research Institute of Maternal and Child Health & Precision Medicine, National and Kapodistrian University of Athens, Athens, Greece*

Abstract

The present review aimed to explore the treatment of metabolic bone diseases using anti-sclerostin antibodies, including Osteoporosis, Osteogenesis Imperfecta, Hypophosphatemia, Paget's disease, Fibrous Dysplasia, Multiple Myeloma, Fluorosis, and McCune- Albright Syndrome. These disorders representing metabolic bone diseases are elaborated in the present work. Literature was searched from publicly available databases including PubMed, Scopus, and the Web of Science. Most studies, showed that bone mineral density rose and the risk of fracture was decreased in individuals after being treated with anti-sclerostin antibodies. However, the possibility that these antibodies may trigger cardiovascular events or venous thromboembolism was mentioned as a reason for alarm. Even though anti-sclerostin antibodies have shown promise in treating metabolic bone disorders, additional study is required to determine whether or not they pose any safety concerns.

Keywords: Antibodies, Bone, Osteoporosis, Romosozumab, Sclerostin

Introduction

Sclerostin, a glycoprotein primarily produced by osteocytes, has emerged as a critical regulator of bone dynamics. Generated by the SOST locus, sclerostin is essential for proper bone development and remodeling. Inhibiting the Wnt/-catenin signaling pathway, which is necessary for osteoblast development and bone production, is its primary mode of action[1]. Sclerostin inhibits osteoblast development by binding to low-density lipoprotein receptor-related proteins 5 and 6 (LRP5/6), affecting bone remodeling and strength. Sclerostin is secreted by osteoblasts, the cells responsible for making bones, in reaction to mechanical tension, making these cells mechanosensors. Sclerostin plays a role in the fine-tuning of bone homeostasis in this way. However, significant sclerostin levels limit bone development and decrease bone density, increasing the risk of fractures and contributing to disorders like osteoporosis[2]. The connection between alterations in sclerostin levels and illnesses such as osteogenesis imperfecta and ankylosing spondylitis further attest to the tremendous impact of this protein on bone health. By elucidating the molecular basis for sclerostin's role in metabolic bone disorders, novel treatment methods, such as monoclonal antibodies targeting sclerostin, may be developed to improve bone health and lessen the severity of these ailments.

Furthermore, the complex function of sclerostin in bone

The authors have no conflict of interest.

Corresponding author: *George I. Lambrou, First Department of Pediatrics, National and Kapodistrian University of Athens, Choremeio Research Laboratory, Thivon & Levadeias 8, 11527, Goudi, Athens, Greece*

E-mail: *glamprou@med.uoa.gr*

Edited by: *Konstantinos Stathopoulos*

Accepted *29 October 2024*

physiology has piqued the attention of researchers in bone medicine. Sclerostin-targeting monoclonal antibodies are now being explored as a potential treatment for bone diseases. Clinical studies of the antibody romosozumab have shown promising results because it can counteract sclerostin's adverse effects on bone growth. These antibodies have tremendous therapeutic promise for osteoporosis by boosting bone density and decreasing fracture risk. However, assessing their possible off-target effects and long-term safety is crucial. An understanding of the pathophysiology of metabolic bone diseases, including osteogenesis imperfecta and ankylosing spondylitis, may be gained by research on the role of sclerostin in these disorders[3]. Elevated sclerostin in ankylosing spondylitis provides insight into the connection between inflammatory diseases and bone abnormalities. In contrast, altered sclerostin levels in osteogenesis imperfecta emphasize the delicate balance between bone production and resorption. If these complex relationships are better understood, more precise and efficient treatments for certain diseases may be developed. Finally, the many functions of sclerostin in bone health and its connections with different metabolic bone disorders demonstrate the need for novel therapeutics that attempt to alter its effects. The more we learn about sclerostin, the more we can use it to treat illnesses that influence bone health, eventually enhancing the quality of life for those afflicted.

Lastly, injecting anti-sclerostin antibodies is the standard method of administration[3]. Typically, they are injected subcutaneously, or just beneath the skin, into the fatty tissue. Common injection sites include the upper arm, thigh, etc. Injections may be administered daily, weekly, or monthly, depending on the treatment plan and the patient's condition. Injections may be given to specific individuals as seldom as once every several weeks. A doctor or nurse usually delivers injections; however, some patients may be trained to provide themselves with shots at home. Some pain from the injections is expected, although it is often minimal and short-lived.

Therefore, the present review explores the role of the anti-sclerostin antibodies in treating osteoporosis (OP), Paget's Disease (PD), Osteogenesis Imperfecta (OI), Hypophosphatemia (HP), Fibrous Dysplasia (FD), Multiple Myeloma (MM), Fluorosis (FR), McCune-Albright Syndrome (MAS) and Gaucher's Disease (GD) among other metabolic bone diseases.

Anti-Sclerostin Antibodies and Mechanism of Action

Anti-Sclerostin Antibodies

Anti-sclerostin antibodies, a subtype of monoclonal antibodies, specifically targets the protein sclerostin[4]. Sclerostin, primarily produced by osteocytes, the cells responsible for bone formation and maintenance, is pivotal in regulating bone metabolism. Its critical function lies in inhibiting the activity of osteoblasts, the cells tasked with building bone tissue. When osteoblast activity is suppressed, it leads to reduced bone formation, ultimately contributing to conditions like osteoporosis and other bone-related diseases. These diseases are characterized by insufficient bone production or excessive bone resorption, significantly elevating the risk of fractures[5]. Anti-sclerostin antibodies can potentially promote bone production, reestablishing this equilibrium and enhancing bone health.

Mechanism of Action

Biologic drugs known as anti-sclerostin antibodies specifically target and neutralize sclerostin, a protein that prevents bone growth[6]. Anti-sclerostin antibodies offer a promising therapeutic option for metabolic bone diseases due to their ability to enhance bone production and mineral density by inhibiting sclerostin. These antibodies employ a multi-faceted mechanism of action. Osteoblasts, the cells responsible for bone formation, are at the heart of this process. Initially, anti-sclerostin antibodies bind to the sclerostin protein, effectively obstructing its interaction with its receptor, LRP5/6. This interaction is pivotal in preventing the Wnt signaling pathway, which is crucial in regulating bone growth, from being suppressed by sclerostin[7]. Anti-sclerostin antibodies improve the Wnt signaling pathway and promote bone growth by inhibiting sclerostin[3].

Second, anti-sclerostin antibodies may boost the activity of osteoblasts, the cells responsible for manufacturing and depositing new bone tissue, by elevating the expression of essential genes involved in bone formation, such as Runx2 and Osterix[4]. This leads to increased bone formation and a greater population of active osteoblasts. The intricate interplay between bone resorption and production regulates the behavior of osteoclasts, the cells responsible for breaking down aging bone structures. Anti-sclerostin antibodies play a vital role in preserving this balance, as they boost bone formation while reducing bone resorption. Furthermore, these antibodies may inhibit the expression of genes crucial for osteoclast development and function, directly decreasing osteoclast activity[8].

Anti-sclerostin antibodies operate by inhibiting sclerostin, stimulating bone growth and reducing bone resorption. This mechanism increases bone mineral density and strength in individuals with metabolic bone disorders, potentially reducing the risk of fractures and enhancing their overall quality of life. These antibodies have been developed and applied in therapeutic contexts as one example of their medical utility[3]. Postmenopausal women with osteoporosis have seen significant benefits from Romosozumab, a monoclonal antibody that enhances bone mineral density and substantially reduces fracture risk. Another promising monoclonal antibody for osteoporosis treatment is Blosozumab, specifically designed to target sclerostin.

Treatment of Metabolic Bone Diseases by Anti-Sclerostin Antibodies

Up to date, multiple sclerostin antibodies are in clinical trials for the treatment of osteoporosis. However, only one antibody has been approved by the United States Food and Drug Administration (FDA) as well as the European Medicines Agency (EMA), namely Romosozumab for the treatment of post-menopausal osteoporosis. Romosozumab has shown excellent effectiveness in the treatment of osteoporosis[4,9,10]. Multiple clinical studies have investigated the effectiveness of Romosozumab for the treatment of osteoporosis, some of which included the FRAME[11], the STRUCTURE[12], the ARCH[13], and the BRIDGE clinical trials[14].

Osteoporosis

A loss in bone density and an increase in bone fragility describe osteoporosis, a metabolic bone condition that may increase the risk of fractures[15]. It's prevalent, especially among women after menopause, and it may significantly affect daily functioning and quality of life. Osteoporosis may be treated with anti-sclerostin antibodies or by lifestyle changes, including increasing physical exercise and taking calcium and vitamin D supplements[15].

Antibodies against sclerostin, block the protein's ability to suppress bone growth. Osteocytes, cells found inside the bone matrix, secrete sclerostin, which are essential to healthy bone remodeling[16]. Bone mass is usually maintained by a balance of bone resorption and bone production; however, this is disrupted in osteoporosis. Sclerostin reduces bone mass and increases bone fragility by blocking the development of osteoblasts from bone marrow stromal cells[17].

Anti-sclerostin antibodies may stimulate bone development because they prevent sclerostin from doing its function. Treatment with anti-sclerostin antibodies, for instance, significantly increased bone mineral density (BMD) in the lumbar spine and hip compared to a placebo in postmenopausal women with osteoporosis trial[16]. The therapy group also had a reduced rate of vertebral fractures compared to the placebo group.

Osteogenesis imperfecta

Collagen deficiency, a protein crucial to bone strength and shape, causes the uncommon genetic condition of osteogenesis imperfecta (OI)[18]. People suffering from OI manifest fragile bone structure, and they may also have additional symptoms such as joint hypermobility, hearing loss, and bluish sclerae. Physical therapy, orthopedic surgery, and drugs to increase bone density and decrease fracture risk are among the ways that OI may be treated. Anti-sclerostin antibodies are a novel and promising therapy for OI[19]. As bone cells secrete sclerostin, which helps control the balance between bone growth and breakdown[20]. Sclerostin has a role in keeping bone growth and loss rate in balance in healthy people. In contrast, increasing sclerostin levels cause less bone growth and more bone resorption in OI patients[18]. Bone density may be increased, and bone production stimulated with anti-sclerostin antibodies.

Hypophosphatemia

Bone growth and mineralization are affected by hypophosphatemia. Bone mineralization is impaired due to a lack of the enzyme tissue-nonspecific alkaline phosphatase (TNSALP), which is caused by mutations in the gene encoding for TNSALP[21]. Low TNSALP levels are responsible for bone fragility, skeletal abnormalities, and increased risk of fractures seen in people with hypophosphatemia[22]. By inhibiting the Wnt signaling system, which is required for bone development and remodeling, sclerostin prevents new bone from forming[22]. Anti-sclerostin antibodies promote bone growth and improve bone mineral density by inhibiting sclerostin. Anti-sclerostin antibodies are a viable therapy option for hypophosphatemia because of their mode of action[23].

Subcutaneous administration of the anti-sclerostin antibody romosozumab improved bone mineral density and bone strength in individuals with hypophosphatemia as compared to placebo. Physical function and quality of life also improved for romosozumab-treated individuals. Moreover, burosumab patients had considerably higher bone mineral density and better skeletal structure than placebo patients[21]. Patients given burosumab also demonstrate enhancements in their quality of life and increases in muscular strength and lung function.

Several benefits may come from using anti-sclerostin antibodies to treat hypophosphatemia. Anti-sclerostin antibodies stimulate bone production by attacking the underlying mechanism of the illness, as opposed to standard therapies for hypophosphatemia, such as vitamin D supplements and bisphosphonates[22]. Because of this, bone density increases and fracture rates decrease. Patients with hypophosphatemia have also increased their physical function and quality of life after receiving anti-sclerostin antibodies[21].

Paget's disease

Bones affected by Paget's disease undergo abnormally high rates of bone resorption and unusual bone growth[18]. Bone abnormalities, discomfort, and fractures are all possible outcomes. Paget's disease is thought to be connected to a mix of hereditary and environmental factors, while the precise relationship is unknown. Bisphosphonates, calcitonin, and surgery are only some options for treating Paget's disease[24]. Anti-sclerostin antibodies have recently gained much attention as a possible therapy for Paget's disease. Animal models for Paget's disease have indicated that anti-sclerostin antibodies improve bone mass and strength.

Anti-sclerostin antibodies have also been studied for

their potential to treat the disease in clinical studies[25-28]. Furthermore, Ralston et al. (2019) assert that bisphosphonates may significantly mitigate the high bone turnover in active PDB[26-28]. Bisphosphonates were shown to reduce total ALP by 50.1% as compared to placebo (592 individuals), and the relative risk (RR) of bisphosphonates normalizing total ALP was 9.96[29]. The same study compared nitrogen-containing bisphosphonates to those without nitrogen and found that the former was more successful in normalizing total ALP than the latter (212 participants). As compared to pamidronate (90 individuals) and risedronate sodium (347 people), zoledronic acid was more effective at lowering total ALP[26-28].

Serum total ALP concentrations have been investigated with the duration of the impact of several bisphosphonates. According to Gutteridge et al. (1996), total ALP levels were maintained in 53% of the risedronate sodium group and 14% of the etidronate group after six months of treatment in a randomized study comparing oral risedronate sodium 30 mg daily for two months with oral etidronate 400 mg for six months[30]. The HORIZON Paget's study found that after five years of follow-up, 88% of patients treated with a single dosage of 5 mg zoledronic acid intravenously had average blood total ALP. Still, only 47% of patients treated with oral risedronate sodium had typical serum total ALP[30]. Patients who had normal ALP levels after the preliminary trial were the only ones who could participate in the follow-up phase of the research.

Serum alkaline phosphatase levels were shown to be considerably lower when treated with romosozumab as compared to placebo. As also compared to placebo, bone mineral density was also raised in the lumbar spine and hip with romosozumab[31,32]. These findings support the potential efficacy of anti-sclerostin antibodies like romosozumab in treating Paget's disease. Patients with Paget's disease may benefit from anti-sclerostin antibodies because they promote bone growth while decreasing bone resorption[24].

Fibrous dysplasia

Bone weakening and deformity may occur due to fibrous dysplasia, which causes bones to develop abnormally[33]. Overexpression of cAMP is the direct outcome of a mutation in the *GNAS* gene, which causes aberrant bone growth. One or more bones may be affected by fibrous dysplasia, which is commonly detected in children and adolescents. Treatment for fibrous dysplasia now focuses on symptom management and avoiding consequences since a therapy is not yet available. Since anti-sclerostin antibodies target the underlying bone metabolic mechanisms that lead to fibrous dysplasia, they are a possible therapy for the condition.

Multiple myeloma

Multiple Myeloma (MM), is a hematologic malignancy, causing anemia and bone deterioration by promoting the growth of malignant plasma cells that secrete monoclonal immunoglobulins[34]. Because of the widespread nature of the illness, a combination of therapies, including chemotherapy, immunomodulatory drugs, and drugs that specifically target the bones, is necessary for effective treatment. Metabolic bone disease, a side effect of multiple myeloma, manifests in osteoporosis, osteolytic lesions, and elevated bone resorption[35]. Reduced bone formation and increased bone resorption due to increased sclerostin synthesis by malignant plasma cells contribute to developing metabolic bone disease in multiple myeloma[35]. Anti-sclerostin antibodies have also shown promise in treating bone disease caused by MM in clinical studies. Patients with MM had more significant increase in bone mineral density and lower risk of vertebral fractures when treated with romosozumab. In addition, it has been found that romosozumab also improved quality-of-life indicators.

Fluorosis

Fluorosis is a condition derived from excessive diet fluoride. Its primary effect is a reduction in bone mineralization, increasing the likelihood of fractures[3]. Although fluorosis symptoms may be treated, a cure has yet to be discovered. Fluorosis has a new, potentially effective therapy on the horizon, i.e. anti-sclerostin antibodies[8]. Anti-sclerostin antibodies, have been shown to stimulate bone mineralization, which may also effectively reverse fluorosis. Anti-sclerostin antibodies have been studied as a possible therapy for fluorosis. Treatment with anti-sclerostin antibodies enhanced bone density and decreased fracture risk in a rat model of fluorosis. Bone mineralization and fluoride levels were improved after therapy with anti-sclerostin antibodies in a mouse model of fluorosis. Anti-sclerostin antibodies have been the subject of human clinical studies to assess their safety and potential usefulness.

McCune-Albright syndrome

McCune-Albright Syndrome (MAS) symptoms include aberrant bone development, endocrine abnormalities, and skin pigmentation; the illness is rarely inherited[36]. Mutations in the *GNAS1* gene, which controls the activation of many signaling pathways, including those involved in bone metabolism, are a possible origin of this disorder. Osteoporosis, osteopenia, and fibrous dysplasia are metabolic bone disorders that may affect people with MAS. Anti-sclerostin antibodies have been the subject of many clinical trials for treating metabolic bone disorders caused by MAS. In mice, anti-sclerostin antibodies were used to cure fibrous dysplasia, a common bone condition linked to MAS. Treatment with sclerostin inhibitors enhanced bone production and improved bone density, suggesting they may help treat MAS-related bone problems.

According to a study by McClung (2017), in a phase II dose-ranging study, 419 postmenopausal women with low bone mass were randomly assigned to receive subcutaneous injections of romosozumab at doses ranging from 70 mg

every three months to 210 mg every month or placebo[15]. Subcutaneous teriparatide of 20 g/day (open-label) or alendronate 70 mg/week (also open-label) was given to the remaining 15 patients. The 210 mg monthly dosage of romosozumab resulted in average increases in bone mineral density (BMD) of 11.3% in the lumbar spine (LS) and 4.1% in the whole hip (TH) after 12 months. These boosts were enormous as compared to teriparatide and alendronate[15]. Comparing placebo, romosozumab, and teriparatide treatments, the loss in BMD at the 1/3 radial location was 0.9%, 1.3%, and 1.7%, respectively[15].

Bone formation indicators increased rapidly, peaked between 1 and 3 months, and declined to below baseline levels for the remaining 12 months of therapy[15]. The time of this reaction is extremely close to that of romosozumab's anabolic impact in cynomolgus monkeys. Patients who kept taking romosozumab showed no increase in bone production or resorption indicators throughout the second year of the research. In line with these findings, LS BMD rose by 3.8% after a year of romosozumab treatment, less than the 4.1% rise in the first year of therapy[15].

Gaucher's disease

Lack of the enzyme glucocerebrosidase causes an uncommon genetic illness known as Gaucher's disease[37]. Bone pain, osteoporosis, and fractures are among the symptoms brought on by the buildup of a fatty molecule called glucocerebroside in many organs, including the bones. Consequently, Gaucher's disease is now understood to be a metabolic bone disease, and various therapies are available to alleviate its symptoms. Anti-sclerostin antibodies are a potential treatment option for Gaucher's disease. Anti-sclerostin antibodies have been reported to treat bone loss and fractures in clinical studies for people with Gaucher's disease.

Adverse Effects of Anti-Sclerostin Antibodies Treatment

Like any medical treatment, anti-sclerostin antibodies have potential inefficiencies and limitations.

Hypocalcemia

Hypocalcemia, may occur due to anti-sclerostin antibodies treatment. Calcium may be released from bones and into circulation due to the enhanced bone growth promoted by anti-sclerostin antibodies[38]. Muscle cramps, convulsions, and cardiac arrhythmias/palpitations are only some of the signs of hypocalcemia. Patients receiving anti-sclerostin antibodies may benefit from taking calcium and vitamin D supplements to lower their risk of hypocalcemia[39].

Besides bone resorption, the breakdown and elimination of old bone tissue are other areas where anti-sclerostin antibodies fall short. Bone resorption, a process of bone remodeling, plays a crucial role in keeping bones healthy and strong. Too much inhibition of bone resorption may lead to the buildup of aged, fragile bone tissue, raising the likelihood of fractures[38]. Because anti-sclerostin antibodies do not directly inhibit bone resorption, using them may cause an imbalance between bone production and bone resorption, impairing bone quality and raising the risk of fractures.

Hyperostosis

Abnormal bone thickening (hyperostosis) is another possible reaction to anti-sclerostin antibodies[38]. Due to an imbalance between bone resorption and bone production, extra bone tissue may accumulate when anti-sclerostin antibodies enhance bone growth. Extreme instances of hyperostosis, which may cause discomfort and deformity, may need surgical removal of the extra bone tissue.

Joint Pain

Patients under anti-sclerostin antibodies therapy manifest joint discomfort[40]. Increased bone growth driven by anti-sclerostin antibodies may place stress on joints; this may be a contributing factor to joint discomfort. However, the specific process is not fully known. Most cases of joint pain fall into the mild to moderate severity range, making them amenable to treatment with over-the-counter medications.

Moreover, the poor effectiveness of anti-sclerostin antibodies in high-risk groups, such as the elderly, postmenopausal women, and patients with severe osteoporosis, is one of the critical drawbacks of this treatment. Bone loss and fracture risk are both increased in these groups of patients. However, bone loss in these groups often results from a confluence of issues, such as hormonal shifts, poor diet, and lack of exercise[15].

Injection Site Reactions

Subcutaneous or intravenous injections are the most common routes of administration for anti-sclerostin antibodies[41]. Common adverse effects of these drugs include injection site responses, pain, edema, and redness. Most of the time, these responses aren't severe and go away within a few days[15]. Extreme reactions at the injection site are uncommon but may be life-threatening. Hypersensitivity responses, injection site reactions, and cardiovascular events are only a few of the rare side effects reported despite these medications' largely positive safety profiles. Furthermore, it is still unclear whether or not these treatments are safe to take over the long term, and there is some evidence to suggest that doing so may raise the user's chance of developing cancers like breast and prostate[15]. Patients having a history of cancer or other comorbidities may be excluded from their usage due to these safety risks.

Circulatory Problems

Anti-sclerostin antibody therapy has been linked to an elevated risk of cardiovascular events, including heart attack and stroke. This may be because sclerostin prevents

excessive calcium from accumulating in the arteries, a process known as vascular calcification. Anti-sclerostin antibodies may increase arterial calcification and the risk of cardiovascular events by blocking sclerostin. Besides, the risk of venous thromboembolism (blood clots in the veins) was also higher in patients treated with anti-sclerostin antibodies[42]. Although the specific process is unknown, it is believed to be connected to sclerostin' s function in controlling the coagulation cascade. An imbalance in the coagulation cascade and an increased risk of blood clots may result from anti-sclerostin antibodies inhibiting sclerostin[42].

Comparing Anti-Sclerostin Antibody Treatment With Other Therapies

Several types of bone disorders may be treated with drugs apart from anti-sclerostin antibodies, such as bisphosphonates, and teriparatide groups. These remedies all work in various ways and have varying degrees of success and potential side effects.

Osteoporosis, Paget's disease, and bone metastases are usually treated with bisphosphonates. These medications slow or stop the mechanism through which osteoclasts tear down bone tissue. Bisphosphonates aid in bone density preservation and minimize breakage. Bisphosphonates used to treat bone loss include alendronate, risedronate, ibandronate, and zoledronic acid[29]. Anti-sclerostin antibodies, on the other hand, promote bone growth. Additionally, osteoporosis may be treated with teriparatide, a synthetic version of the parathyroid hormone (PTH)[43]. Bone development and density may be boosted with the use of teriparatide. Teriparatide stimulates bone production, in contrast to bone-resorbing bisphosphonates. Teriparatide is injected subcutaneously once a day. Studies have proven that all three categories of drugs may increase bone density and decrease fracture risk. Teriparatide medication, for instance, significantly increased bone density and reduced vertebral fractures in postmenopausal women with osteoporosis. Bisphosphonates lower the risk of vertebral and non-vertebral fractures in individuals with osteoporosis.

Positive outcomes from therapeutic studies with anti-sclerostin antibodies have also been seen. Seefried et al. (2017) reported a randomized controlled trial showing that romosozumab improved bone density and reduced the risk of fractures in postmenopausal women with osteoporosis more effectively than alendronate[23]. Bisphosphonates have a relatively low risk of adverse effects as compared to other medications. However, they may still cause problems, including stomach discomfort, joint pain, and even jawbone necrosis in rare cases. Teriparatide is contraindicated in individuals with a history of bone malignancy, hypercalcemia, or Paget's disease and has adverse effects such as nausea, dizziness, and leg cramps. Adverse effects such as injection site responses and hypersensitivity reactions have also been linked to anti-sclerostin antibodies.

The method of administration is also crucial when comparing various drugs. Teriparatide and anti-sclerostin antibodies are injected subcutaneously, whereas bisphosphonates are taken orally or intravenously. Different drugs have different recommended dosing schedules and treatment durations. Conversely, teriparatide may be taken once daily for up to two years, whereas bisphosphonates are typically administered every three months or yearly. In most cases, patients get anti-sclerostin antibodies once a month for up to a year.

As compared to teriparatide and anti-sclerostin antibodies, bisphosphonates seem more cost-effective. Biological drugs such as teriparatide and anti-sclerostin antibodies are costlier to develop. Teriparatide has been proven more effective than anti-sclerostin antibodies in boosting bone density in individuals with severe osteoporosis, even though their mechanisms of action are comparable. Treatment decisions should consider the patient's age, sex, medical history, and bone density test findings. Each medication's cost, route of administration and possible adverse effects must also be considered.

Denosumab is a monoclonal antibody that specifically targets RANKL, a protein involved in bone resorption. Denosumab prevents bone loss by blocking RANKL, which boosts bone density and strength. Indications for denosumab include osteoporosis, bone metastases, and giant bone-cell tumors. Denosumab may considerably enhance bone density and decrease the incidence of fractures. Denosumab and anti-sclerostin antibodies have both shown promise as osteoporotic treatments. There are, however, distinctions between the two drugs. Denosumab prevents bone loss while increasing bone growth through anti-sclerostin antibodies. Denosumab is administered every six months intravenously, while anti-sclerostin antibodies are injected monthly for a year.

Future Perspectives for Anti-Sclerostin Antibody Treatment

Anti-sclerostin antibodies enhance bone development, increase bone mass and strength by inhibiting sclerostin production. Although anti-sclerostin antibodies have only recently been introduced to the clinical practice, continuing studies have shown various promising avenues for further development.

Combination therapies

Creating combinatory treatments is a potential next step in the evolution of anti-sclerostin antibody therapy. Some bone illnesses may need more than only anti-sclerostin antibodies ability to stimulate bone growth. Anti-sclerostin antibodies may be more effective with other medications inhibiting bone resorption, such as bisphosphonates. Combination therapy may also permit lower dosages of individual drugs, minimizing potential side effects.

Long-term safety

Evaluating long-term safety is another crucial step for anti-sclerostin antibody therapy. Although encouraging outcomes have been shown in short-term clinical studies, it is still unclear what impact would have, using medications for prolonged periods of time. For instance, increased bone mass and strength may have unintended consequences, especially in individuals with preexisting bone disorders. More studies are required to investigate the optimal treatments and duration to lessen these dangers.

Personalized medicine

Anti-sclerostin antibody therapy, is a potential future avenue as in the case of customized medicine for many other diseases. Each patient's care would be tailored to their unique genetic and environmental characteristics in a customized treatment. This strategy has the potential to provide more efficient therapies with fewer adverse effects. Moreover, customized medicine may aid in determining which individuals are most suited for therapy with anti-sclerostin antibodies.

Development of Biosimilars

Biologic medications like anti-sclerostin antibodies are complicated since they are produced from live cells. Consequently, their high production cost means they are not widely available to patients. Similar to biological medications, but differently manufactured, biosimilars may provide a less expensive therapy alternative. Patient outcomes may also improve if biosimilars are developed and made more widely available.

Implications in the Clinical Practice

Important implications in the clinical practice arise from using anti-sclerostin antibodies in treating metabolic bone illnesses such as osteoporosis, Paget's disease, and Gaucher's disease. Bone mass and strength may be increased, and fracture risk decreased with anti-sclerostin antibodies. Appropriate patient selection is essential for anti-sclerostin antibody therapy. Currently, osteoporosis in postmenopausal women and men at high risk of fracture may be treated with anti-sclerostin antibodies. Patients who will most benefit from this medication must be identified, as must those with a higher chance of experiencing unwanted side effects. To assure the safety and effectiveness of anti-sclerostin antibody therapy, patients with underlying bone illnesses such as Paget's or Gaucher's disease may need further monitoring and follow-up.

Monitoring bone mineral density and other indicators of bone metabolism consistently has crucial implications for the clinical practice. Clinical studies using anti-sclerostin antibodies have increased bone density and strength; however, the medications' long-term effects are not yet established. Bone density and other indicators may be monitored regularly to determine whether and when therapy has to be adjusted. Clinicians must also be aware of the risks associated with anti-sclerostin antibody therapy. There is a chance for side effects such as fractures and jaw osteonecrosis, even though these medications have typically been well-tolerated in clinical studies. Patients should be aware of these dangers and given enough counseling and monitoring to keep them safe.

To guarantee the safety and effectiveness of these medications, clinicians should be conversant with the correct dose and administration practices. Patients need to feel confident in their ability to self-administer these medications. Thus, education is also crucial. The price tag attached to anti-sclerostin antibody therapy is also a factor to be considered. Due to their high cost, some patients may be unable to afford them. The possible advantages and hazards of anti-sclerostin antibody therapy, as well as the patient's financial position and insurance coverage, should be considered when clinicians and patients collaborate to choose the best course of treatment.

Discussion and Conclusions

Osteoporosis, Paget's disease, Osteogenesis imperfecta, Hypophosphatemia, Fibrous dysplasia, Multiple myeloma, Fluorosis, McCune-Albright Syndrome, and Gaucher's disease are all metabolic bone diseases that anti-sclerostin antibodies may help. These antibodies encourage bone growth and increase bone bulk and strength by inhibiting sclerostin. Although anti-sclerostin antibodies have only recently been introduced to clinical practice, continuing studies have shown various promising avenues for further development. Anti-sclerostin antibody therapy has great potential for further development and optimization, particularly in combination treatments, long-term safety evaluation, personalized medicine, the production of biosimilars, and the treatment of rare bone disorders. Improved patient outcomes and lower healthcare costs are possible if these medications become more widely available due to the development of biosimilars.

However, anti-sclerostin antibody therapy's potential advantages and hazards require further study. The potential for long-term side effects, such as fractures, must be carefully evaluated to ensure these therapies are safe. Despite these obstacles, creating anti-sclerostin antibodies provides a potential new strategy for treating metabolic bone disorders. Millions of individuals throughout the globe may benefit from these medications, which may enhance their bone health and overall quality of life. Optimization and safe, successful implementation into clinical practice will need ongoing study and development. Combination therapy, long-term safety evaluation, customized medicine, the creation of biosimilars, and the treatment of uncommon bone disorders are just a few of the potential paths highlighted by ongoing research that might lead to the advancement of these treatments. Anti-sclerostin antibody therapy will benefit significantly from continuing investigation into these questions.

Authors' contributions

OT: Drafted the manuscript, reviewed literature. GIL: Proof-edited the manuscript and gave final permission for publication. All authors read and approved the manuscript.

References

1. Link TM. Metabolic Bone Disease. In: Cassar-Pullicino VN, Davies AM, editors. Measurements in Musculoskeletal Radiology. Berlin, Heidelberg: Springer Berlin Heidelberg; 2020. p. 785-807.
2. Yepes JF. Dental Manifestations of Pediatric Bone Disorders. Current osteoporosis reports 2017;15(6):588-92.
3. Fabre S, Funck-Brentano T, Cohen-Solal M. Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases. Journal of clinical medicine 2020;9(11):3439.
4. Rauner M, Taipaleenmäki H, Tsourdi E, Winter EM. Osteoporosis Treatment with Anti-Sclerostin Antibodies-Mechanisms of Action and Clinical Application. Journal of clinical medicine 2021;10(4):787.
5. Tamplen M, Fowler T, Markey J, Knott PD, Suva LJ, Alliston T. Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation. Head & neck 2018;40(7):1453-60.
6. Ominsky MS, Boyce RW, Li X, Ke HZ. Effects of sclerostin antibodies in animal models of osteoporosis. Bone 2017;96:63-75.
7. Davidson G. LRPs in WNT Signalling. In: Schulte G, Kozielewicz P, editors. Pharmacology of the WNT Signaling System. Cham: Springer International Publishing; 2021. p. 45-73.
8. Clarke BL. Anti-sclerostin antibodies: utility in treatment of osteoporosis. Maturitas 2014;78(3):199-204.
9. Iolascon G, Liguori S, Paoletta M, Toro G, Moretti A. Anti-sclerostin antibodies: a new frontier in fragility fractures treatment. Therapeutic advances in musculoskeletal disease 2023;15:1759720x231197094.
10. Yu S, Li D, Zhang N, Ni S, Sun M, Wang L, et al. Drug discovery of sclerostin inhibitors. Acta pharmaceutica Sinica B 2022;12(5):2150-70.
11. Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. The New England journal of medicine 2016;375(16):1532-43.
12. Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. The Lancet 2017;390(10102):1585-94.
13. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. The New England journal of medicine 2017;377(15):1417-27.
14. Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, et al. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. The Journal of clinical endocrinology and metabolism 2018;103(9):3183-93.
15. McClung MR. Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential. Therapeutic advances in musculoskeletal disease 2017;9(10):263-70.
16. Jacobsen CM. Application of anti-Sclerostin therapy in non-osteoporosis disease models. Bone 2017;96:18-23.
17. MacNabb C, Patton D, Hayes JS. Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges. Journal of osteoporosis 2016;2016:6217286.
18. Glorieux FH, Devogelaer JP, Durigova M, Goemaere S, Hemsley S, Jakob F, et al. BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2017;32(7):1496-504.
19. Little DG, Peacock L, Mikulec K, Kneissel M, Kramer I, Cheng TL, et al. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta. Bone 2017;101:96-103.
20. Sinder BP, Lloyd WR, Salemi JD, Marini JC, Caird MS, Morris MD, et al. Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age. Bone 2016;84:222-9.
21. Bianchi ML, Bishop NJ, Guañabens N, Hofmann C, Jakob F, Roux C, et al. Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2020;31(8):1445-60.
22. Van Caenegem E, Wierckx K, Taes Y, Schreiner T, Vandewalle S, Toye K, et al. Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI). European journal of endocrinology 2015;172(2):163-71.
23. Seefried L, Baumann J, Hemsley S, Hofmann C, Kunstmann E, Kiese B, et al. Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. The Journal of clinical investigation 2017;127(6):2148-58.
24. Pathak JL, Bravenboer N, Klein-Nulend J. The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases. Frontiers in endocrinology. 2020;11:405.
25. Cronin O, Forsyth L, Goodman K, Lewis SC, Keerie C, Walker A, et al. Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone. BMJ open. 2019;9(9):e030689.
26. Ralston SH, Corral-Gudino L, Cooper C, Francis RM, Fraser WD, Gennari L, et al. Clinical Guidelines on Paget's Disease of Bone. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2019;34(12):2327-9.
27. Ralston SH, Corral-Gudino L, Cooper C, Francis RM, Fraser WD, Gennari L, et al. Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 2019;34(4):579-604.
28. Ralston SH, Taylor JP. Rare Inherited forms of Paget's Disease and Related Syndromes. Calcified tissue international 2019;104(5):501-16.
29. Corral-Gudino L, Tan AJ, Del Pino-Montes J, Ralston SH. Bisphosphonates for Paget's disease of bone in adults. The Cochrane database of systematic reviews 2017;12(12):Cd004956.
30. Gutteridge DH, Retallack RW, Ward LC, Stuckey BG, Stewart GO, Prince RL, et al. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study. Bone 1996;19(4):387-94.
31. Tosi LL, Warman ML. Mechanistic and therapeutic insights gained from studying rare skeletal diseases. Bone. 2015;76:67-75.
32. Yip RKH, Chan D, Cheah KSE. Mechanistic insights into skeletal development gained from genetic disorders. Current topics in developmental biology 2019;133:343-85.

33. Leet AI, Collins MT. Current approach to fibrous dysplasia of bone and McCune-Albright syndrome. Journal of children's orthopaedics 2007;1(1):3-17.
34. McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, et al. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood 2017;129(26):3452-64.
35. Kleber M, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care? Expert review of hematology 2019;12(8):651-63.
36. Hannan FM, Newey PJ, Whyte MP, Thakker RV. Genetic approaches to metabolic bone diseases. British journal of clinical pharmacology 2019;85(6):1147-60.
37. Ivanova MM, Dao J, Kasaci N, Friedman A, Noll L, Goker-Alpan O. Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease. Frontiers in endocrinology. 2022;13:1029130.
38. Mukaddam MA, Hvisdas C, Sulaj A, Patel K, Tran R. Experience With Anti-Sclerostin Antibody for Osteoporosis Patient With End-Stage Renal Disease on Hemodialysis. Journal of the Endocrine Society 2021;5(Supplement_1):A192-A.
39. Pundole X, Lopez-Olivo MA, Suarez-Almazor ME, Lu H. Anti-sclerostin antibodies for the treatment of osteoporosis. LID - CD012640. (1469-493X (Electronic)).
40. McClung MR. Romosozumab for the treatment of osteoporosis. Osteoporosis and sarcopenia 2018;4(1):11-5.
41. Hesse E, Schröder S, Brandt D, Pamperin J, Saito H, Taipaleenmäki H. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI insight 2019;5(9).
42. Zeng C, Guo C, Cai J, Tang C, Dong Z. Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease. Diabetes & vascular disease research 2018;15(2):99-105.
43. Wheeler AL, Tien PC, Grunfeld C, Schafer AL. Teriparatide treatment of osteoporosis in an HIV-infected man: a case report and literature review. AIDS (London, England) 2015;29(2):245-6.